| 2026-08-07 | Press release | Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-05 | Press release | Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-05 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-16 | Press release | Jul 16, 2026 Arcutis Expands Board of Directors with Appointment of Chris Peetz Read More |
| 2026-07-16 | 8-K | Form 8-K, Item 5.02 |
| 2026-07-15 | Press release | Jul 15, 2026 Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Read Mor |
| 2026-07-08 | Press release | Jul 08, 2026 FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Read M |
| 2026-07-02 | Press release | Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-30 | Press release | Jun 30, 2026 Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with C Read M |
| 2026-06-29 | Press release | Jun 29, 2026 FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Chil Read M |
| 2026-06-12 | Deck | Arcutis June 2026 Corporate Presentation |
| 2026-06-09 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-05 | Press release | Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-03 | Press release | Jun 03, 2026 New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Read Mo |
| 2026-05-26 | Press release | May 26, 2026 Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference Read More |
| 2026-05-06 | Press release | Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-06 | Deck | 1st Quarter 2026 Financial Results |
| 2026-05-06 | Press release | Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-27 | Press release | Apr 27, 2026 Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% t Read M |
| 2026-04-22 | Press release | Apr 22, 2026 Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatolo Read M |
| 2026-04-21 | Proxy | Definitive proxy statement |
| 2026-04-15 | Press release | Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 |
| 2026-03-31 | Press release | Mar 31, 2026 Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference Read More |
| 2026-03-28 | Press release | Mar 28, 2026 Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Toda Read M |
| 2026-03-18 | Press release | Mar 18, 2026 Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters a Read M |
| 2026-03-10 | Press release | Mar 10, 2026 Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumila Read M |
| 2026-03-05 | Press release | Mar 05, 2026 Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Su Read M |
| 2026-03-03 | Press release | Mar 03, 2026 Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Voluntee Read M |
| 2026-03-01 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-27 | Press release | Feb 27, 2026 Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference Read More |
| 2026-02-25 | Deck | Arcutis Fourth Quarter 2025 Financial Results & Business Update |
| 2026-02-25 | Press release | Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-02-25 | Press release | Feb 25, 2026 Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Read Mor |
| 2026-02-25 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-25 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-02 | Press release | Feb 02, 2026 Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumila Read M |